Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s

Multiple myeloma (MM) is the second most prevalent hematologic malignancy. Although the use of bortezomib (BTZ) significantly improves MM therapy, intrinsic and acquired drug resistance to BTZ remains a major clinical problem. In this study, we find that Cdc37, a key co-chaperone of Hsp90, is downre...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncogenesis
Autori principali: Zang, Meirong, Guo, Jiaojiao, Liu, Lanting, Jin, Fengyan, Feng, Xiangling, An, Gang, Qin, Xiaoqi, Wu, Yangbowen, Lei, Qian, Meng, Bin, Zhu, Yinghong, Guan, Yongjun, Deng, Shuhui, Hao, Mu, Xu, Yan, Zou, Dehui, Wu, Minghua, Qiu, Lugui, Zhou, Wen
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058164/
https://ncbi.nlm.nih.gov/pubmed/32139666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-020-0216-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi